APA (7th ed.) Citation

Werth, V., Pearson, D., Owaka, J., Feng, R., Concha, J. S., Patel, B., . . . White, B. (2019). OP0241 SAFETY AND EFFICACY OF LENABASUM IN AN OPEN-LABEL EXTENSION OF A PHASE 2 STUDY OF LENABASUM IN REFRACTORY SKIN-PREDOMINANT DERMATOMYOSITIS (DM) SUBJECTS. Annals of the rheumatic diseases, 78, 199-200. https://doi.org/10.1136/annrheumdis-2019-eular.3397

Chicago Style (17th ed.) Citation

Werth, Victoria, et al. "OP0241 SAFETY AND EFFICACY OF LENABASUM IN AN OPEN-LABEL EXTENSION OF A PHASE 2 STUDY OF LENABASUM IN REFRACTORY SKIN-PREDOMINANT DERMATOMYOSITIS (DM) SUBJECTS." Annals of the Rheumatic Diseases 78 (2019): 199-200. https://doi.org/10.1136/annrheumdis-2019-eular.3397.

MLA (9th ed.) Citation

Werth, Victoria, et al. "OP0241 SAFETY AND EFFICACY OF LENABASUM IN AN OPEN-LABEL EXTENSION OF A PHASE 2 STUDY OF LENABASUM IN REFRACTORY SKIN-PREDOMINANT DERMATOMYOSITIS (DM) SUBJECTS." Annals of the Rheumatic Diseases, vol. 78, 2019, pp. 199-200, https://doi.org/10.1136/annrheumdis-2019-eular.3397.